pharma news today glp-1 obesity drugs A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes health pharma news today obesity

Key differential aspects of the group of glucagon-like peptide-1 receptor agonist drugs There are several arGLP-1 s approved or under study for the use in DM2: exenatide (exenatide and exenatide LAR or weekly), liraglutide, lixisenatide, dulaglutide, semaglutide, albiglutide (withdrawn from the market), and efpeglenatide (in clinical development)

Billings, MD, MMSc The next steps involve launching Phase 3 clinical trials, which will study eloralintide in a much larger and more diverse group of participants to further examine eloralintides effectiveness and long-term safety, she added

The second-line ADMs included GLP1-R agonists, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sodium-glucose cotransporter 2 (SGLT2) inhibitors

I think we had all been expecting less, given that the launch of Novos previous obesity drug, Saxenda, wasnt very successfulalbeit with about 5% weight loss. However, investors have now definitely taken note, changing the landscape of pharma stocks

Farnesoid X receptor interacts with cAMP response element binding protein to modulate glucagon-like peptide-1 (736) amide secretion by intestinal L cell